557MO Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial.
Saved in:
| Title: | 557MO Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic anal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial. |
|---|---|
| Authors: | Coutzac, C.1 (AUTHOR), Bigot, F.2 (AUTHOR), Vansteene, D.3 (AUTHOR), Dos Santos, M.4 (AUTHOR), Ghiringhelli, F.5 (AUTHOR), You, B.6 (AUTHOR), Lambert, A.7 (AUTHOR), Gomez-Roca, C.A.8 (AUTHOR), Abdeddaim, C.9 (AUTHOR), Neuzillet, C.10 (AUTHOR), Jeannot, E.11 (AUTHOR), Guerini Rocco, E.12 (AUTHOR), Frige, G.13 (AUTHOR), Mazzarella, L.14 (AUTHOR), Dupain, C.15 (AUTHOR), Kamal, M.15 (AUTHOR), Legrand, F.16 (AUTHOR), Jimenez, M.16 (AUTHOR), Filleron, T.17 (AUTHOR), Le Tourneau, C.2 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS415-S415. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.09.1748 |
